Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Anavex Life Sciences Corp.NASDAQ: AVXL
Net Income · Q1 FY2026 · quarter ended Dec 2025
Net income declines year over year
Q1 FY2026 net income of $5.68M (cash outflow) fell 53.1% year over year, behind the -14.1% change in trailing-twelve-month net income. Sequentially, it fell 42.2% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$28.15M (-39.3%) for the fiscal year ending Sep 2026, a slowdown from the +7.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$5.68M-42.2% QoQ
- Last fiscal yearSep 2025
- -$46.38M+7.8% YoY
- LTMDec 2025
- -$39.95M-14.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -53.1% | -40.5% | +12.6 pp |
| 1 year | +7.8% | -39.3% | -47.2 pp |
| 3-year CAGR | -1.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (46.38M) USD
- Year-over-year change
- -7.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (46.38M) | -7.8% |
| FY2024 | 2024-09-30 | (43M) | +9.5% |
| FY2023 | 2023-09-30 | (47.51M) | +1.0% |
| FY2022 | 2022-09-30 | (47.98M) | -26.6% |
| FY2021 | 2021-09-30 | (37.91M) | — |
Net Income vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.1% is the 9th highest of 10, against a peer median of +81.9%.
- Over three fiscal years its annual growth of -1.1% compares with a peer median of -7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $328.6M USD | +96.4% | -4.1% | 412.0% | |
| LTM Sep 2026 | $307.94M USD | +141.2% | -20.0% | — | |
| LTM Mar 2026 | $290.01M USD | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $259.47M USD | +76.5% | +66.1% | — | |
| LTM Mar 2026 | $221.3M USD | +374.9% | -34.1% | 247.5% | |
| LTM Mar 2026 | €146.23M EUR | +81.9% | -7.0% | 93.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M USD | +80.3% | +49.3% | — |
| LTM Mar 2026 | $118.44M USD | +10.2% | +3.2% | 6450.8% | |
| LTM Mar 2026 | $59.14M USD | -242.2% | -44.1% | 166.4% | |
| LTM Dec 2025 | $39.95M USD | -14.1% | -1.1% | — | |
| Peer median (excluding AVXL) | — | +81.9% | -7.0% | 288.9% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M |
| Change in Working Capital | (706K) | 5.36M | 2.51M | 2.75M | (4.22M) |
| Accounts Receivables | (4.29M) | 5.94M | 484K | 260K | 1.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 751K | (914K) | 497K | 5.31M | (5.38M) |
| Other Working Capital | 2.83M | 331K | 1.52M | (2.81M) | (478K) |
| Other Non-Cash Items | 0 | 0 | 845K | 0 | 0 |
| Operating Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 22M | 29.65M | 11.98M | 12.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24K | (707K) | 29.65M | 11.98M | (2.71M) |
| Financing Cash Flow | 153.24M | 21.29M | 29.65M | 11.98M | 9.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 122.86M | (2.95M) | 1.87M | (18.84M) | (29.61M) |
| Free Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.